Indication
Breast Atypical Hyperplasia
3 clinical trials
3 products
2 drugs
Clinical trial
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Product
AcolbifeneDrug
TamoxifenClinical trial
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In SituStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Topical 4-OHT gelDrug
VarlilumabClinical trial
Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast CancerStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Omega-3-Acid Ethyl Esters